

8<sup>th</sup> November, 2017

**BSE Limited**

1<sup>st</sup> Floor, New Trading Wing,  
Rotunda Bldg, P.J. Towers,  
Dalal Street, Fort,  
Mumbai- 400 001

**National Stock Exchange of India Ltd.,**

Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra-Kurla Complex,  
Mumbai – 400 051.

Dear Sir / Madam,

**BSE SCRIP CODE – 500302, 912459**  
**NSE SYMBOL – PEL**


**Sub: Intimation of Conference Call with Investors/ Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the details of the Conference Call with investors/ analysts.

Kindly take the above on record.

Thanking you,

Yours truly,  
For **Piramal Enterprises Limited**



**Chanda Makhija Thadani**  
**Assistant Company Secretary**

**Piramal Enterprises Limited**

CIN : L24110MH1947PLC005719

Registered Office : Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013, India

Secretarial Dept : Ground Floor, B Block, Agastya Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, Maharashtra 400070, India  
T+91 22 3802 3084/3083/3103 F+91 22 3802 3083

[piramal.com](http://piramal.com)



## Piramal Enterprises Limited

### Q2 & H1 FY2018 Earnings Conference Call

**Mumbai, India, November 08, 2017:** Piramal Enterprises Limited ('PEL', NSE: PEL, BSE: 500302) will be hosting a conference call of investors / analysts with Chairman & its Management team on **9<sup>th</sup> Nov 2017 (Thursday) at 6:00 PM (IST) to discuss Q2 & H1 FY2018 Results.**

The dial-in numbers for the call are as below:

Event	Location & Time	Telephone Number
Conference call on 09 Nov 2017	India – 6:00 PM IST	+91 22 3960 0668 (Primary Number)
		1800 120 1221 / 1800 200 1221 (Toll free number)
	USA – 7:30 AM (Eastern Time – New York)	Toll free number 18667462133
	UK – 12:30 PM (London Time)	Toll free number 08081011573
	Singapore – 8:30 PM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 8:30 PM (Hong Kong Time)	Toll free number 800964448
For online registration	<a href="http://services.choruscall.in/diamondpass/registration?confirmationNumber=2431417">http://services.choruscall.in/diamondpass/registration?confirmationNumber=2431417</a>	

For further information, please contact:

**For Investors:**

Hitesh Dhaddha / Bhavna Sinyal | Investor Relations  
Piramal Enterprises Limited  
Contact: +91 22 3046 6444 / +91 22 3046 6570  
[investor.relations@piramal.com](mailto:investor.relations@piramal.com)

**For Media Queries:**

Dimple Kapur | Corporate Communications  
Contact: +91 22 3351 4269  
[dimple.kapur@piramal.com](mailto:dimple.kapur@piramal.com)

## **About Piramal Enterprises Limited**

Piramal Enterprises Limited (PEL) is one of India's large diversified companies, with a presence in Financial Services, Pharmaceuticals and Healthcare Insights & Analytics. PEL's consolidated revenues were over US\$1.3 billion in FY2017, with 51% of revenues generated from outside India.

In Financial Services, PEL provides comprehensive financing solutions to real estate companies. The division's Corporate Finance Group (CFG) also provides senior and mezzanine growth capital to various businesses across varied sectors that are integral part of India's growth story. The Division has also launched Distressed Asset Investing platform that will invest in equity and/or debt in assets across sectors (other than real estate) to drive restructuring with active participation in turnaround. The total funds under management under all these businesses are over US\$5.5 billion. The Company has recently launched a retail housing finance vertical. The Company also has strategic alliances with top global funds such as APG Asset Management, Bain Capital Credit, CPPIB Credit Investment Inc. and Ivanhoé Cambridge (CDPQ). PEL also has long term equity investments worth ~US\$1 billion in Shriram Group, a leading financial conglomerate in India.

In Pharma, through an end-to-end manufacturing capabilities across 13 global facilities and a large global distribution network to over 100 countries, PEL sells a portfolio of niche differentiated pharma products and provides an entire pool of pharma services (including in the areas of injectable, HPAPI etc.). The Company is also strengthening its presence in the Consumer Product segment in India.

PEL's Healthcare Insights & Analytics business, Decision Resources Group, is the premier provider of healthcare analytics, data & insight products and services to the world's leading pharma, biotech and medical technology companies and enables them to take informed business decisions.

PEL is listed on the BSE Limited and the National Stock Exchange of India Limited in India.